EZZ Life Science Holdings Limited (EZZ.AX)
AUD 2.92
(-0.68%)
AUD 2.92
(-0.68%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 1.4 Million AUD | 65.45% |
| 2023 | 846.91 Thousand AUD | 171.1% |
| 2022 | 312.39 Thousand AUD | 15.02% |
| 2021 | 271.61 Thousand AUD | 723.06% |
| 2020 | 33 Thousand AUD | 3299900.0% |
| 2019 | 1.00 AUD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.55 Million AUD | 399.19% |
| 2024 FY | 1.4 Million AUD | 65.45% |
| 2024 Q4 | 1.4 Million AUD | 0.0% |
| 2024 Q2 | 1.55 Million AUD | 0.0% |
| 2023 Q1 | 730.53 Thousand AUD | 133.85% |
| 2023 FY | 846.91 Thousand AUD | 171.1% |
| 2023 Q4 | 312.39 Thousand AUD | -63.11% |
| 2023 Q3 | 846.91 Thousand AUD | 15.93% |
| 2023 Q2 | 730.53 Thousand AUD | 0.0% |
| 2022 Q1 | 494.54 Thousand AUD | 82.08% |
| 2022 FY | 312.39 Thousand AUD | 15.02% |
| 2022 Q4 | 312.39 Thousand AUD | 0.0% |
| 2022 Q3 | 312.39 Thousand AUD | -36.83% |
| 2022 Q2 | 494.54 Thousand AUD | 0.0% |
| 2021 Q1 | 385.7 Thousand AUD | 1075.58% |
| 2021 FY | 271.61 Thousand AUD | 723.06% |
| 2021 Q3 | 271.61 Thousand AUD | -29.58% |
| 2021 Q4 | 271.61 Thousand AUD | 0.0% |
| 2021 Q2 | 385.7 Thousand AUD | 0.0% |
| 2020 Q4 | 32.81 Thousand AUD | 0.0% |
| 2020 FY | 33 Thousand AUD | 3299900.0% |
| 2020 Q1 | - AUD | 0.0% |
| 2020 Q3 | 32.81 Thousand AUD | 0.0% |
| 2019 FY | 1.00 AUD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Anatara Lifesciences Ltd | -671.09 Thousand AUD | 308.793% |
| Zelira Therapeutics Limited | 1.25 Million AUD | -11.889% |
| Biome Australia Limited | 1.88 Million AUD | 25.807% |
| Patrys Limited | - AUD | -Infinity% |
| Orthocell Limited | 1.17 Million AUD | -19.085% |
| Imugene Limited | - AUD | -Infinity% |
| Noxopharm Limited | -2.35 Million AUD | 159.392% |
| PYC Therapeutics Limited | -17.99 Million AUD | 107.786% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| Prescient Therapeutics Limited | - AUD | -Infinity% |
| Proteomics International Laboratories Limited | - AUD | -Infinity% |
| Cynata Therapeutics Limited | 108.2 Thousand AUD | -1194.957% |
| CSL Limited | 8.93 Billion AUD | 99.984% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 10.62 Million AUD | 86.814% |
| Starpharma Holdings Limited | 2.4 Million AUD | 41.811% |
| Nanollose Limited | - AUD | -Infinity% |
| Memphasys Limited | 164.76 Thousand AUD | -750.441% |
| Invex Therapeutics Ltd | -94.98 Thousand AUD | 1575.206% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | - AUD | -Infinity% |
| Botanix Pharmaceuticals Limited | 1.2 Million AUD | -15.861% |
| Island Pharmaceuticals Limited | -877.24 Thousand AUD | 259.728% |
| Race Oncology Limited | 16.4 Thousand AUD | -8443.351% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 17.31 Million AUD | 91.905% |
| Dimerix Limited | - AUD | -Infinity% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 2.00 AUD | -70059650.0% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 1.00 AUD | -140119400.0% |
| BTC Health Limited | - AUD | -Infinity% |
| Acrux Limited | 147 Thousand AUD | -853.194% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| Biotron Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | 214.72 Thousand AUD | -552.562% |
| AdAlta Limited | -1.67 Million AUD | 183.428% |
| Radiopharm Theranostics Limited | -987.41 Thousand AUD | 241.906% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 221.85 Thousand AUD | -531.576% |
| Paradigm Biopharmaceuticals Limited | - AUD | -Infinity% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 97.11 Thousand AUD | -1342.791% |
| Actinogen Medical Limited | 108.82 Thousand AUD | -1187.52% |
| Immuron Limited | 1.58 Million AUD | 11.575% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |